Rilzabrutinib

N/A

Report date: 2026/05/21 20:00:22
NME

Base Information

Drug NameRilzabrutinib
Drug Alias NameRilzabrutinbWayrilzPRN-1008SAR-444671
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsImmunoglobulin G4-Related DiseaseImmune System DiseasesPemphigus +[13] 
Global Approved IndicationsPurpura, Thrombocytopenic, Idiopathic
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited Arab Emirates
Original Approved Date2025/07/08
Country/TerritoryCzechiaBelgiumBulgaria +[42] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesPrincipia Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesSanofi-Aventis Recherche Et DéveloppementSanofi BVSanofi +[8] 
Inactive CompaniesN/A
Active IndicationsImmunoglobulin G4-Related DiseaseChronic UrticariaDermatitis, Atopic +[9] 
Inactive IndicationsImmune System DiseasesPemphigusThrombocytopenia +[4] 

Other Information

ATC CodeL01EL
Related LinksWikipediaDrugBankKEGG